Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679488 | 0.85 | MC4R (0.43) | MC4R | |
| SCHEMBL5332549 | 0.84 | MC4R (0.70) | MC4RLIMK2 | |
| SCHEMBL8332423 | 0.84 | GPR119 (0.49) | LIMK2STSKDM4EGPR119MAPT | |
| SCHEMBL4701631 | 0.82 | BRD4 (0.43) | MC4RSTSKDM4EPKMGPR119 | |
| SCHEMBL7799838 | 0.82 | LIMK2 (0.55) | MC4RLIMK2STSKDM4EPKM | |
| SCHEMBL13671270 | 0.82 | MC4R (0.46) | MC4RSTSKDM4EGPR119MAPT | |
| SCHEMBL5338150 | 0.81 | MC4R (0.65) | MC4RLIMK2 | |
| SCHEMBL6608621 | 0.80 | GPR119 (0.53) | KDM4EPKMGPR119MAPTTHRB | |
| SCHEMBL5338194 | 0.80 | MC4R (0.64) | MC4R | |
| SCHEMBL4701517 | 0.80 | MC4R (0.65) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | MC4R 1/4885LIMK2 4194/4885STS 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.